Based in New York City, Lexeo Therapeutics is a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated.  Building on groundbreaking research from Weill Cornell Medicine and the University of California San Diego, Lexeo partners with preeminent institutions on the cutting edge of gene therapy research.  Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4 associated Alzheimer's disease programs, and is led by pioneers and experts with decades of collective experience in genetic medicines, rare disease drug development, manufacturing and commercialization. 

For more information, please visit www.lexeotx.com.

Sarepta Therapeutics

Woodline Partners

Alexandria Venture Investments

Omega Funds

PBM Capital Group

Invus

Alzheimer's Drug Discovery Foundation

Janus Henderson Investors

Longitude Capital

Lundbeckfonden Ventures

CAM Capital

Verition Fund Management

D1 Capital Partners

Eventide

Gray’s Creek Capital Partners

Intus Capital

Laurion Capital Management

Lexeo Therapeutics

Happy holidays to the team members, friends, family, partners, physicians and patients who have contributed to Lexeo’s work in 2023!

In 2023, Lexeo participated in numerous local events to join forces with patient advocates who are raising awareness about devastating diseases such as #Alzheimer’s, #FriedreichsAtaxia and #ArrhythmogenicCardiomyopathy.
 
Look back on some of our favorite photos from the year with Friedreich's Ataxia Research Alliance (FARA) and Alzheimer's Association®!

We are pleased to announce the FDA has granted Orphan Drug designation and Fast Track designation to LX2020, our #genetherapy candidate designed to treat arrhythmogenic cardiomyopathy caused by mutations in the PKP2 gene (PKP2-ACM).

Read the full press release here: https://lnkd.in/eq6wzhin

$LXEO shares began trading on Nasdaq last month.
 
Here's a peek behind the curtain of the biggest highlights from IPO day, ringing the Nasdaq closing bell and our event celebrating the Lexeo team for making this possible!
 
#LexeoListed

Yesterday, we reported our Q3 financial results and operational highlights. Check out the highlights below or read the full press release here: https://bit.ly/3Njy60f

Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases.

Vertex Pharmaceuticals is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases.

Vertex Pharmaceuticals

Lexeo is a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated.

Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Lexeo Therapeutics, Inc. Common Stock

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 4, 2024 10:54 PM	4032f176
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 4, 2024 10:54 PM	b677784f
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	5d1554c5
crunchbase profile	general
li profile	general	Mar 4, 2024 10:54 PM	c6d04f52
translate crunchbase fundingrounds	general
peers	general
news basic	general	Mar 4, 2024 10:54 PM	1c617cfa
bundesanzeiger	filings
financials download nd	financials
private financials	financials

LXEO

COM:LEXEOTX

Lexeo

Last Close

4.22

14/02 21:00

Market Cap

541.62M

Beta: -

Volume Today

250.19K

Avg: -